視網膜疾病治療市場規模、佔有率和成長分析（按疾病、疾病類型、治療技術、給藥途徑、最終用戶和地區分類）－2026-2033年產業預測

全球視網膜疾病治療市場規模預計在 2024 年達到 128.6 億美元，從 2025 年的 140.2 億美元成長到 2033 年的 279.3 億美元，在預測期（2026-2033 年）內複合年成長率為 9%。

全球視網膜疾病盛行率呈上升趨勢，影響超過2.53億人，對醫療保健系統造成沉重的經濟負擔。人口老化，尤其是50歲及以上人口數量的成長（他們佔視力障礙患者的81%），預計將進一步推動眼科護理需求。糖尿病視網膜病變等疾病發生率的上升與糖尿病發生率的上升密切相關，尤其是在新興市場。視網膜疾病管理專家的日益增加預計將促進市場成長。此外，各地區加強昂貴視網膜治療的報銷政策預計將進一步推動市場擴張，並為該產業在視網膜疾病治療方案方面取得重大進展奠定基礎。

推動全球視網膜疾病藥物市場發展的因素

眼科疾病發生率的不斷上升，尤其是在已開發國家，正顯著推動全球視網膜治療市場的發展。糖尿病視網膜病變等疾病影響全球數百萬患者，凸顯了有效治療方法的緊迫感。此外，預計老齡化黃斑部病變（AMD）病例的增加也將促進市場擴張。加強眼科疾病健康教育的努力，尤其是在發展中地區，正在推動早期療育和治療，從而刺激對視網膜疾病治療的需求。人們對這類治療方案日益成長的認知和需求，將顯著促進市場成長。

限制全球視網膜疾病藥物市場的因素

全球視網膜疾病治療市場的擴張面臨許多重大挑戰。視網膜治療的高昂費用是一大障礙，而患者往往擔憂短期副作用和潛在的長期併發症，例如雷射眼科手術等治療後可能發生的感染疾病和發炎。此外，諸如氣動視網膜固定術等手術技術也存在風險，例如意外鞏膜穿孔，這可能會影響患者的選擇，並進一步阻礙市場成長。除了這些問題之外，開發中國家醫療基礎設施的不足也為全球視網膜疾病治療的發展帶來了額外的障礙。

視網膜疾病治療市場的全球趨勢

由於先進技術的湧現，特別是基因治療領域的發展，全球視網膜疾病治療市場正經歷顯著成長。視網膜基因治療等創新技術正在革新遺傳性視網膜疾病（如萊伯氏先天性黑朦症）的治療，例如，Luxturna等治療方法展現出恢復患者視力的潛力。視網膜治療領域正迅速發展，目前有許多基於重組病毒的基因療法正在進行臨床試驗。這一趨勢凸顯了人們對個人化醫療和標靶治療日益成長的關注，隨著新型治療方法獲得監管部門核准並惠及更多患者，預計市場將大幅擴張。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球視網膜疾病治療市場規模（按疾病類型和複合年成長率分類）（2025-2031 年）

• 老齡化黃斑部病變
• 糖尿病視網膜病變
• 視網膜剝離
• 視網膜母細胞瘤
• 黃斑皺褶
• 黃斑裂孔
• 漂浮物

全球視網膜疾病治療市場規模（按疾病類型和複合年成長率分類）（2025-2031 年）

• 遺傳
• 與老齡化相關的

全球視網膜疾病藥物市場規模（依治療技術及複合年成長率分類）（2025-2031 年）

• 雷射
• 冷凍療法
• 植入
• 壓迫療法
• 氣動視網膜固定術
• 鞏膜扣帶術
• 玻璃體切除手術

全球視網膜疾病治療市場規模（依給藥途徑及複合年成長率分類）（2025-2031 年）

• 口服
• 局部用藥
• 玻璃體內注射
• 其他

全球視網膜疾病藥物市場規模（依最終用戶分類）及複合年成長率（2025-2031 年）

• 醫院
• 門診手術中心
• 家庭醫療保健
• 其他

全球視網膜疾病藥物市場規模（依分銷管道分類）及複合年成長率（2025-2031 年）

• 直接競標
• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

全球視網膜疾病治療市場規模及複合年成長率（2025-2031）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2023 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2023）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2021-2023年營收年比比較

主要企業簡介

• Regeneron Pharmaceuticals, Inc.（USA）
• Roche Holding AG（Switzerland）
• Novartis AG（Switzerland）
• Allergan（part of AbbVie）（USA）
• Bayer AG（Germany）
• Oculis（Switzerland）
• REGENXBIO Inc.（USA）
• Adverum Biotechnologies, Inc.（USA）
• Kodiak Sciences Inc.（USA）
• EyePoint Pharmaceuticals, Inc.（USA）
• Apellis Pharmaceuticals, Inc.（USA）
• Iveric Bio, Inc.（USA）（Acquired by Astellas）
• Annexon Biosciences（USA）
• Hemera Biosciences（USA）（Acquired by Roche）
• Gyroscope Therapeutics（UK）（Acquired by Novartis）
• Graybug Vision, Inc.（USA）
• Clearside Biomedical, Inc.（USA）
• Ocuphire Pharma, Inc.（USA）
• Lineage Cell Therapeutics, Inc.（USA）
• Ocugen, Inc.（USA）

結論與建議

Global Retinal Disease Therapeutics Market size was valued at USD 12.86 Billion in 2024 and is poised to grow from USD 14.02 Billion in 2025 to USD 27.93 Billion by 2033, growing at a CAGR of 9% during the forecast period (2026-2033).

The prevalence of retinal disorders is escalating globally, impacting over 253 million individuals and exerting considerable financial pressure on healthcare systems. The aging population, particularly those over 50 who represent 81 percent of vision-impaired patients, is set to intensify demands on ophthalmic care. Rising rates of conditions like diabetic retinopathy are linked to the growing incidence of diabetes, particularly in emerging markets. As the availability of specialized professionals in retinal disease management increases, market growth is anticipated. Additionally, enhanced reimbursement policies for costly retinal treatments in various regions are expected to further stimulate market expansion, positioning the industry for significant advancements in therapeutic solutions for retinal diseases.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Disease Therapeutics Market Segments Analysis

Global Retinal Disease Therapeutics Market is segmented by disorder, disorder type, treatment techniques, route of administration, end-users, distribution channel and region. Based on disorder, the market is segmented into macular degeneration, diabetic eye disease, retinal detachment, retinoblastoma, macular pucker, macular hole and floaters. Based on disorder type, the market is segmented into genetic and age related. Based on treatment techniques, the market is segmented into laser, freezing, implanting, indenting, pneumatic retinopexy, scleral buckling and vitrectomy. Based on route of administration, the market is segmented into oral, topical, intravitreal and others. Based on end-users, the market is segmented into hospitals, ambulatory surgical centers, home healthcare and others. Based on distribution channel, the market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Retinal Disease Therapeutics Market

The increasing incidence of eye-related diseases, especially in developed nations, is significantly propelling the global market for retinal therapeutics. A considerable number of individuals are affected by conditions such as diabetic retinopathy, with millions suffering globally, highlighting the urgent need for effective treatments. Moreover, the anticipated rise in cases of age-related macular degeneration (AMD) will further contribute to market expansion. Efforts to enhance health education around eye disorders are encouraging early intervention and treatment, particularly in developing regions, thereby driving demand for retinal disease treatments. This growing awareness and need for therapeutic solutions will bolster market growth significantly.

Restraints in the Global Retinal Disease Therapeutics Market

The expansion of the global retinal disease therapeutics market faces several significant challenges. High costs associated with retinal treatment therapies pose a major barrier, while patients often express concerns regarding short-term side effects and potential long-term complications, including infections and inflammation that may occur after procedures like laser eye surgery. Moreover, surgical methods such as pneumatic retinopexy carry risks, including unintentional scleral perforation, which can influence patient choices and further inhibit market growth. Compounding these issues, inadequate healthcare infrastructure in developing countries creates additional obstacles for the advancement of retinal disease therapies on a global scale.

Market Trends of the Global Retinal Disease Therapeutics Market

The Global Retinal Disease Therapeutics market is experiencing significant growth driven by the emergence of advanced technologies, particularly in gene therapy. Innovations such as retinal gene therapy are revolutionizing treatments for inherited retinal disorders like Leber's congenital amaurosis, with therapies like Luxturna showcasing the potential to restore vision in affected patients. With numerous gene therapies currently in clinical trials and employing recombinant viruses, the landscape of retinal therapeutics is rapidly evolving. This trend emphasizes the increasing focus on personalized medicine and targeted treatments, positioning the market for substantial expansion as novel therapies increasingly gain regulatory approvals and reach patients in need.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Retinal Disease Therapeutics Market Size by Disorder & CAGR (2025-2031)

• Market Overview
• Macular Degeneration
• Diabetic Eye Disease
• Retinal Detachment
• Retinoblastoma
• Macular Pucker
• Macular Hole
• Floaters

Global Retinal Disease Therapeutics Market Size by Disorder Type & CAGR (2025-2031)

• Market Overview
• Genetic
• Age Related

Global Retinal Disease Therapeutics Market Size by Treatment Techniques & CAGR (2025-2031)

• Market Overview
• Laser
• Freezing
• Implanting
• Indenting
• Pneumatic Retinopexy
• Scleral Buckling
• Vitrectomy

Global Retinal Disease Therapeutics Market Size by Route Of Administration & CAGR (2025-2031)

• Market Overview
• Oral
• Topical
• Intravitreal
• Others

Global Retinal Disease Therapeutics Market Size by End-Users & CAGR (2025-2031)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Home Healthcare
• Others

Global Retinal Disease Therapeutics Market Size by Distribution Channel & CAGR (2025-2031)

• Market Overview
• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Retinal Disease Therapeutics Market Size & CAGR (2025-2031)

• North America (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (part of AbbVie) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oculis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyePoint Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apellis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iveric Bio, Inc. (USA) (Acquired by Astellas)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Annexon Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hemera Biosciences (USA) (Acquired by Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gyroscope Therapeutics (UK) (Acquired by Novartis)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Graybug Vision, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocuphire Pharma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lineage Cell Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocugen, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations